← Back to list
08.01.93f, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Effective date
Jan 1, 2026
Identified
Jun 19, 2026
Summary
Independence Blue Cross updated policy 08.01.93f effective 01/01/2026 to add LEQEMBI IQLIK (weekly subcutaneous maintenance formulation) to the list of amyloid-directed monoclonal antibodies for Alzheimer's disease. The policy maintains its existing position: these drugs remain non-covered as either benefit exclusions (depending on plan) or experimental/investigational treatments. Billing teams must ensure claims for all four drugs (aducanumab, lecanemab-irmb, donanemab-azbt, and the new LEQEMBI IQLIK formulation) are denied appropriately.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01By 12/31/2025: Billing team must update billing system and denial protocols to recognize LEQEMBI IQLIK as a non-covered service effective 01/01/2026.
02Verify in the system that all four drugs—aducanumab (J0172), lecanemab-irmb (J0174), donanemab-azbt (J0175), and LEQEMBI IQLIK—are configured to auto-deny as either benefit exclusions or experimental/investigational services based on individual plan terms.
03Update internal reference materials and provider communications to include LEQEMBI IQLIK in the list of non-covered amyloid monoclonal antibodies.
04Ensure billing staff and providers understand that claims for these services will be denied and should not be submitted for reimbursement consideration.
If missed: Failure to properly configure denials may result in erroneous approvals and subsequent claim recoveries.
Codes mentioned
J0172J0174J0175
Original notice
08.01.93f, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's DiseaseLowNo effective date · Medical PolicyMA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's DiseaseMediumEffective Mar 5, 2025 · Medical PolicyMA08.151e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's DiseaseMediumEffective Jan 1, 2026 · Medical Policy08.01.93e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer DiseaseHighEffective Jan 1, 2025 · Medical PolicyBrowse every Independence Blue Cross change in the policy list